- Home
- SANG vs ACRS Comparison
SANG vs ACRS Comparison
Compare SANG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- ACRS
- Stock Information
- Founded
- SANG 1984
- ACRS 2012
- Country
- SANG Canada
- ACRS United States
- Employees
- SANG N/A
- ACRS N/A
- Industry
- SANG Computer Software: Programming Data Processing
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- ACRS Health Care
- Exchange
- SANG Nasdaq
- ACRS Nasdaq
- Market Cap
- SANG 153.5M
- ACRS 127.6M
- IPO Year
- SANG 2021
- ACRS 2015
- Fundamental
- Price
- SANG $5.90
- ACRS $1.26
- Analyst Decision
- SANG
- ACRS Strong Buy
- Analyst Count
- SANG 0
- ACRS 7
- Target Price
- SANG N/A
- ACRS $10.67
- AVG Volume (30 Days)
- SANG 3.7K
- ACRS 801.8K
- Earning Date
- SANG 05-08-2025
- ACRS 05-08-2025
- Dividend Yield
- SANG N/A
- ACRS N/A
- EPS Growth
- SANG N/A
- ACRS N/A
- EPS
- SANG N/A
- ACRS N/A
- Revenue
- SANG $241,243,000.00
- ACRS $17,777,000.00
- Revenue This Year
- SANG N/A
- ACRS N/A
- Revenue Next Year
- SANG $2.91
- ACRS $425.96
- P/E Ratio
- SANG N/A
- ACRS N/A
- Revenue Growth
- SANG N/A
- ACRS N/A
- 52 Week Low
- SANG $4.08
- ACRS $0.95
- 52 Week High
- SANG $7.99
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SANG 67.39
- ACRS 43.64
- Support Level
- SANG $5.67
- ACRS $1.20
- Resistance Level
- SANG $5.97
- ACRS $1.46
- Average True Range (ATR)
- SANG 0.13
- ACRS 0.11
- MACD
- SANG 0.06
- ACRS 0.02
- Stochastic Oscillator
- SANG 95.04
- ACRS 41.77
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.